HighTower Advisors LLC Increases Stake in Inhibrx, Inc. (NASDAQ:INBX)

HighTower Advisors LLC increased its position in shares of Inhibrx, Inc. (NASDAQ:INBX – Get Rating) by 0.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 132,708 shares of the company’s stock after buying an additional 808 shares during the period. HighTower Advisors LLC’s holdings in Inhibrx were worth $3,271,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in INBX. Point72 Hong Kong Ltd grew its stake in shares of Inhibrx by 154.6% during the second quarter. Point72 Hong Kong Ltd now owns 2,879 shares of the company’s stock worth $33,000 after acquiring an additional 1,748 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Inhibrx by 633.1% during the third quarter. Nisa Investment Advisors LLC now owns 2,346 shares of the company’s stock worth $47,000 after acquiring an additional 2,026 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Inhibrx by 418.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,704 shares of the company’s stock worth $66,000 after acquiring an additional 2,989 shares during the last quarter. Quantbot Technologies LP grew its stake in shares of Inhibrx by 90.8% during the second quarter. Quantbot Technologies LP now owns 5,915 shares of the company’s stock worth $67,000 after acquiring an additional 2,815 shares during the last quarter. Finally, Legal & General Group Plc grew its stake in shares of Inhibrx by 52.7% during the second quarter. Legal & General Group Plc now owns 8,383 shares of the company’s stock worth $95,000 after acquiring an additional 2,892 shares during the last quarter. Hedge funds and other institutional investors own 72.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Credit Suisse Group restated an “outperform” rating and set a $46.00 price target on shares of Inhibrx in a research note on Tuesday, March 7th. JMP Securities decreased their target price on Inhibrx from $40.00 to $35.00 and set a “market outperform” rating for the company in a report on Wednesday, March 8th. Finally, Lifesci Capital reaffirmed an “outperform” rating on shares of Inhibrx in a report on Wednesday, April 26th.

Inhibrx Trading Up 3.6 %

Shares of NASDAQ:INBX opened at $25.16 on Monday. The company has a market capitalization of $1.10 billion, a PE ratio of -6.39 and a beta of 2.86. Inhibrx, Inc. has a 12-month low of $7.67 and a 12-month high of $34.72. The business has a 50 day moving average of $21.44 and a two-hundred day moving average of $24.51. The company has a current ratio of 7.47, a quick ratio of 7.47 and a debt-to-equity ratio of 13.61.

Inhibrx (NASDAQ:INBX – Get Rating) last posted its quarterly earnings data on Monday, March 6th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.15). Inhibrx had a negative net margin of 12,725.62% and a negative return on equity of 1,961.44%. The business had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.30 million. As a group, analysts forecast that Inhibrx, Inc. will post -4.06 EPS for the current year.

About Inhibrx

(Get Rating)

Inhibrx, Inc, a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.